53 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcas‪t‬ PVI, PeerView Institute for Medical Education

    • Science

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Neal D. Shore, MD, FACS - Changing the Treatment Story With Hormonal Therapy in Prostate Cancer: Challenges and Opportunities for Improving Care Across Disease Settings

    Neal D. Shore, MD, FACS - Changing the Treatment Story With Hormonal Therapy in Prostate Cancer: Challenges and Opportunities for Improving Care Across Disease Settings

    Go online to PeerView.com/QAT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in urologic oncology discusses hormonal therapy in prostate cancer. Upon completion of this activity, participants should be better able to: Summarize the recent safety and efficacy data on novel hormonal therapy for metastatic castration-sensitive prostate cancer (mCSPC), as well as for other prostate cancer settings including castration-resistant (nmCRPC and mCRPC) disease, Counsel patients on current hormonal therapy standards for personalized management of prostate cancer, including for treatment selection based on disease progression, prior therapy, and patient characteristics, Design individualized, evidence-based treatment plans for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors, Manage the spectrum of adverse events associated with novel hormonal therapies in patients with prostate cancer.

    • 50 min
    William K. Oh, MD - Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes

    William K. Oh, MD - Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes

    Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.

    • 1 hr 4 min
    George L. Bakris, MD - Improving Outcomes and Preventing Chronic Kidney Disease Progression: Evaluating the Role of Novel Nonsteroidal Mineralocorticoid Receptor Antagonists

    George L. Bakris, MD - Improving Outcomes and Preventing Chronic Kidney Disease Progression: Evaluating the Role of Novel Nonsteroidal Mineralocorticoid Receptor Antagonists

    Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.

    • 39 min
    Steven Fishbane, MD / Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN - HIF-PH Inhibitors for Anemia in Chronic Kidney Disease: What Are Their Implications in Health-System Pharmacy?

    Steven Fishbane, MD / Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN - HIF-PH Inhibitors for Anemia in Chronic Kidney Disease: What Are Their Implications in Health-System Pharmacy?

    Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD. Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients, Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor.

    • 1 hr 19 min
    Javed Butler, MD, MPH, MBA - Making the Case for Treating Iron Deficiency in Patients With Heart Failure

    Javed Butler, MD, MPH, MBA - Making the Case for Treating Iron Deficiency in Patients With Heart Failure

    Go online to PeerView.com/BFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular diseases and heart failure (HF) research presents a patient case to explore current evidence-based recommendations for diagnosing iron deficiency (ID) to encourage timely and appropriate treatment to improve outcomes in patients with HF. Upon completion of this activity, participants should be better able to: Describe the prevalence of ID in patients with HF and its impact on patient outcomes and quality of life, Interpret laboratory results for diagnosing and monitoring iron status in patients with HF, Apply current clinical guidelines and clinical trial results for iron therapies to improve outcomes in patients with ID and HF.

    • 35 min
    Toni K. Choueiri, MD / David F. McDermott, MD / Nizar M. Tannir, MD, FACP - At the Therapeutic Crossroads for RCC: Investigating the Current Applications, Controversies, and Future Use of Immunotherapy and Targeted Agents

    Toni K. Choueiri, MD / David F. McDermott, MD / Nizar M. Tannir, MD, FACP - At the Therapeutic Crossroads for RCC: Investigating the Current Applications, Controversies, and Future Use of Immunotherapy and Targeted Agents

    Go online to PeerView.com/QRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel targeted, immune-based, and tyrosine kinase inhibitors (TKIs) to the treatment armamentarium. Most recently, these advances have included the validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents (which have led to FDA approvals). Oncology professionals are increasingly challenged to adopt a more nuanced and personalized approach to selecting and sequencing the available treatment options throughout the advanced RCC continuum while taking relevant patient-, disease-, and treatment-related factors into account. During this PeerView Live CME/MOC-certified web broadcast, an expert faculty panel in RCC will share insights on recent clinical trends and how to effectively navigate a complex therapeutic landscape to leverage the potency of newer agents across different disease settings. Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence on the use of multi-targeted tyrosine kinase inhibitors/anti-VEGF agents, immune checkpoint inhibitors, and novel combination approaches in the management of advanced and/or resectable renal cell carcinoma (RCC), Select individualized frontline treatment regimens utilizing targeted and immune-based options for patients with advanced RCC based on relevant patient- and disease-related characteristics, Develop regimens with novel components for patients with pretreated advanced RCC over multiple lines of therapy based on consideration of prior treatment history and patient comorbidities, Manage treatment-related complications with targeted agents and immunotherapy in patients with RCC.

    • 1 hr 3 min

Top Podcasts In Science

Listeners Also Subscribed To